BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 20979555)

  • 1. Treatment of lupus nephritis.
    Dolff S; Berden JH; Bijl M
    Expert Rev Clin Immunol; 2010 Nov; 6(6):901-11. PubMed ID: 20979555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical approach to lupus nephritis: recent advances.
    Molino C; Fabbian F; Longhini C
    Eur J Intern Med; 2009 Sep; 20(5):447-53. PubMed ID: 19712841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Lupus nephritis].
    Morović-Vergles J; Salamon L
    Reumatizam; 2009; 56(2):34-40. PubMed ID: 20429260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review: Lupus nephritis: pathologic features, epidemiology and a guide to therapeutic decisions.
    Ortega LM; Schultz DR; Lenz O; Pardo V; Contreras GN
    Lupus; 2010 Apr; 19(5):557-74. PubMed ID: 20089610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognosis of biopsy-proven lupus nephritis in chinese patients: long term follow-up of 86 cases.
    Shen K; Yu Y; Tang Z; Liu Z; Li L
    Chin Med J (Engl); 1997 Jul; 110(7):502-7. PubMed ID: 9594205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Mycophenolate mofetil for the treatment of lupus nephritis. The case of lupus nephritis--class IV according to WHO--treated with mycophenolate mofetil].
    Suszek D; Wielosz E; Majdan M
    Ann Acad Med Stetin; 2010; 56 Suppl 1():91-4. PubMed ID: 21365951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic options for resistant lupus nephritis.
    Mok CC
    Semin Arthritis Rheum; 2006 Oct; 36(2):71-81. PubMed ID: 16884971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative.
    Groot N; de Graeff N; Marks SD; Brogan P; Avcin T; Bader-Meunier B; Dolezalova P; Feldman BM; Kone-Paut I; Lahdenne P; McCann L; Özen S; Pilkington CA; Ravelli A; Royen-Kerkhof AV; Uziel Y; Vastert BJ; Wulffraat NM; Beresford MW; Kamphuis S
    Ann Rheum Dis; 2017 Dec; 76(12):1965-1973. PubMed ID: 28877866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment options in lupus nephritis.
    McLigeyo SO
    East Afr Med J; 1998 Oct; 75(10):609-13. PubMed ID: 10065198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lupus nephritis.
    Sauter M; Anders HJ
    Minerva Med; 2007 Dec; 98(6):749-58. PubMed ID: 18299686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current status of lupus nephritis.
    Jaryal A; Vikrant S
    Indian J Med Res; 2017 Feb; 145(2):167-178. PubMed ID: 28639592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B Cell Abnormalities in Systemic Lupus Erythematosus and Lupus Nephritis-Role in Pathogenesis and Effect of Immunosuppressive Treatments.
    Yap DYH; Chan TM
    Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31835612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimum therapeutic approaches for lupus nephritis: what therapy and for whom?
    Boumpas DT; Sidiropoulos P; Bertsias G
    Nat Clin Pract Rheumatol; 2005 Nov; 1(1):22-30. PubMed ID: 16932624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunosuppressive therapy in systemic lupus erythematosus.
    Russell AS; Bretscher PA
    J Rheumatol Suppl; 1987 Jun; 14 Suppl 13():194-8. PubMed ID: 3302253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modern therapeutic strategies for paediatric systemic lupus erythematosus and lupus nephritis.
    Marks SD; Tullus K
    Acta Paediatr; 2010 Jul; 99(7):967-74. PubMed ID: 20222881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparison of various cyclophosphamide treatment regimens on the course and outcome of lupus nephritis ].
    Petrović R; Stojanović R; Novicić-Sasić D; Dimitrijević J; Pavlović S; Stojković D; Palić-Obradović D; Stevanović G; Prodanović S
    Srp Arh Celok Lek; 2002 Aug; 130 Suppl 3():19-25. PubMed ID: 12583309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolution of lesions over 10 years in a patient with SLE: flowchart approach to the new International Society of Nephrology (ISN)/Renal Pathology Society (RPS) classification of lupus nephritis.
    Elliot V; Cairns T; Cook HT
    Am J Kidney Dis; 2006 Jan; 47(1):184-90. PubMed ID: 16377401
    [No Abstract]   [Full Text] [Related]  

  • 18. Measurement of interleukin-1 receptor antagonist in patients with systemic lupus erythematosus could predict renal manifestation of the disease.
    Brugos B; Kiss E; Dul C; Gubisch W; Szegedi G; Sipka S; Zeher M
    Hum Immunol; 2010 Sep; 71(9):874-7. PubMed ID: 20538031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Revised classification of lupus nephritis is valuable in predicting renal outcome with an indication of the proportion of glomeruli affected by chronic lesions.
    Hiramatsu N; Kuroiwa T; Ikeuchi H; Maeshima A; Kaneko Y; Hiromura K; Ueki K; Nojima Y
    Rheumatology (Oxford); 2008 May; 47(5):702-7. PubMed ID: 18390590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment for lupus nephritis: a revisit.
    Lai KN; Tang SC; Mok CC
    Nephrology (Carlton); 2005 Apr; 10(2):180-8. PubMed ID: 15877679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.